119-HRES-928 Journalist Public Summary
119 · HRES 928 Affirming support for most-favored-Nation drug pricing for United States patients.
A nonbinding House resolution says Americans shouldn’t pay more for the same prescription drugs than people in other wealthy countries, and backs aligning U.S. prices with the lowest prices abroad, expanding Medicare negotiation, and boosting competition; introduced December 4, 2025 and sent to the House Energy and Commerce Committee.
Headline Summary
House resolution urging that Americans pay no more than peer countries for the same prescription drugs, and supporting steps to align U.S. prices with the lowest international levels.
What It Does
This is a statement of policy (not a law) from the House of Representatives. It says the U.S. should pursue “most-favored-nation” drug pricing—meaning prices here should match the lowest price offered in other developed countries for the same medicine. It also voices support for expanding Medicare’s power to negotiate prices and for encouraging more competition to lower costs. The resolution cites data showing Americans pay more out of pocket and sometimes skip needed medications because of cost.
By the Numbers (as cited in the resolution)
Who’s For It
- Sponsors: Rep. Debbie Dingell (D‑MI) and Rep. Elijah Crane (R‑AZ), signaling bipartisan support.
- Lawmakers who favor tying U.S. prices to the lowest prices in comparable countries to reduce what patients pay at the pharmacy counter.
- Backers who argue the approach could deliver quick savings and prevent Americans from paying more than patients abroad for the same brand-name drugs.
- Supporters of expanded Medicare drug price negotiation and policies that increase market competition (e.g., faster generic/biosimilar entry).
Who’s Against It
- Some pharmaceutical manufacturers and industry-aligned groups, who warn that international reference pricing can reduce revenue needed for research and development.
- Free‑market advocates who oppose government‑linked price benchmarks and prefer competition‑only approaches.
- Analysts who caution that tying U.S. prices to other countries could prompt companies to launch drugs later abroad, limit supply, or withdraw certain products—potentially affecting access.
What’s Next
Status as of December 4, 2025: Introduced and referred to the House Committee on Energy and Commerce. Because this is a House resolution, any adoption would express the chamber’s position but would not, by itself, change federal law or set binding prices.
Discussion